Idorsia sells off Asian operations, top drug licenses to Sosei Heptares in $465M deal
Swiss biopharma Idorsia has sold off a large part of its operations in the Asia Pacific to Sosei Heptares for $465.8 million (400 million CHF) …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
